Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lifitegrast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Xiidra

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xiidra

    Lifitegrast

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 376

    2019 Revenue in Millions : 192

    Growth (%) : 96

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xiidra

    Lifitegrast

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 468

    2020 Revenue in Millions : 376

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xiidra

    Lifitegrast

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 487

    2021 Revenue in Millions : 468

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xiidra

    Lifitegrast

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    2024 ACI Convention
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2019 Revenue in Millions : 192

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF